Drug Profile
Eprotirome
Alternative Names: KB2115Latest Information Update: 21 Dec 2016
Price :
$50
*
At a glance
- Originator Karo Bio
- Class Anilides; Antihyperlipidaemics; Obesity therapies; Small molecules
- Mechanism of Action Thyroid hormone receptor beta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Dyslipidaemias; Hypercholesterolaemia; Obesity
Most Recent Events
- 14 Feb 2012 Discontinued - Phase-II for Dyslipidaemias in Finland (PO)
- 14 Feb 2012 Discontinued - Phase-III for Hypercholesterolaemia in Sweden (PO)
- 04 Oct 2011 Phase-III clinical trials in Hypercholesterolaemia in Sweden (PO)